Filing Flows › Ocular Therapeutix (OCUL) › Q1 2026 › vs Q4 2025
Ocular Therapeutix (OCUL) Q1 2026 vs Q4 2025 (quarter over quarter)
Ocular Therapeutix's revenue fell $2.5M (-19%) from $13.2M in Q4 2025 to $10.8M in Q1 2026.
Ocular Therapeutix, Q1 2026: revenue $10.8M (+0.8% year over year), operating margin -865.5%, net loss $88.6M, operating cash flow −$66.0M. The chart draws each line against Q4 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $10.8M | $13.2M | −$2.5M | -19% |
| Other income, net | $4.7M | $5.1M | −$378K | -7% |
| Net loss | $88.6M | $64.7M | $24.0M | +37% |
| Costs & expenses | $104M | $83.0M | $21.1M | +25% |
| Operating costs | $104M | $83.0M | $21.1M | +25% |
| Cost of revenue | $1.3M | $1.6M | −$265K | -17% |
| Research & development | $66.2M | $50.8M | $15.4M | +30% |
| Sales & marketing | $16.6M | $13.0M | $3.6M | +28% |
| General & admin | $20.0M | $17.7M | $2.3M | +13% |
| Operating cash sources | $88.6M | $64.7M | $24.0M | +37% |
| Depreciation & amortization | $1.3M | $1.2M | $36K | +3% |
| Share-based compensation | $15.6M | $11.4M | $4.2M | +37% |
| Working capital & other | $5.8M | −$2.2M | $8.0M | — |
| Cash used in operations | $66.0M | $54.2M | $11.7M | +22% |
| Net loss absorbed | $88.6M | $64.7M | $24.0M | +37% |
Questions
How much did Ocular Therapeutix's revenue grow quarter over quarter in Q1 2026?
Ocular Therapeutix's revenue fell $2.5M (-19%) from $13.2M in Q4 2025 to $10.8M in Q1 2026.